Haichuang Pharmaceutical (688302.SH): PROTAC drug under development HP518 will release clinical data at the 2024 American Society of Clinical Oncology Annual Meeting

Haichuang Pharmaceutical (688302.SH) announced that clinical research data on the innovative drug HP518 developed by PROTAC independently developed by the company will be released at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. HP518 is an oral, targeted proteolytic chimera (PROTAC) drug independently developed by the company to treat patients with advanced prostate cancer (mCRPC).

Zhitong FinanceMay 27 03:45

Express News | Haichuang Pharmaceutical: Clinical data on the company's self-developed PROTAC drug HP518 was released at the ASCO annual meeting

BreakingsMay 27 03:40

Guo Hong, chief medical officer and core technician of Haichuang Pharmaceutical (688302.SH), left office

Haichuang Pharmaceutical (688302.SH) announced that Guo Hong, the company's chief medical officer and core technical officer, recently applied to resign from his position due to personal reasons and completed the separation procedure. He will no longer hold any position in the company after leaving his job. When Guo Hong assumed the position of Chief Medical Officer, Dr. XINGHAI LI (Li Xinghai), the company's chief technology officer, took over the work. Dr. XINGHAI LI (Li Xinghai) is the company's senior management and core technical staff. Currently, he is fully responsible for the pre-clinical management of the company's new drug development and all global clinical business management.

Zhitong FinanceMay 24 06:44

Haichuang Pharmaceutical (688302): Continued progress in drugs under development

Incident: Recently, the company released its 2023 annual report. In 2023, the company has yet to obtain approval for commercial sales of drugs and no revenue; the company has yet to achieve profit. Net profit attributable to shareholders of listed companies - 29,415.84

財通證券May 13 01:31

Haichuang Pharmaceutical (688302.SH) announced first-quarter results with a net loss of 47.21 million yuan

According to the Zhitong Finance App, Haichuang Pharmaceutical (688302.SH) disclosed its report for the first quarter of 2024. During the reporting period, the company achieved a revenue of 0 yuan; a net profit loss of 47.21 million yuan; and a loss of 52.72 million yuan after deducting non-net profit. Basic earnings per share - $0.48.

Zhitong FinanceApr 26 03:12

Express News | Haichuang Pharmaceutical: First quarter revenue of 0 yuan

BreakingsApr 26 02:51